

Author index to Volume 3

- Aas AT. *See* Salford LG, 267
 Abu Sa'da I. *See* Kirkpatrick DL, 651
 Aggarwal SK. *See* Palma JP, 665
 Al-Baker S. *See* Khokhar AR, 95
 Alberts DS. *See* Lam KS, 219
 Albrecht W. *See* Hoeltl W, 295*
 Alessio E. *See* Sava G, 25
 Allegra CJ. *See* Pai LH, 463
 Alpeter MD. *See* Glisson BS, 359
 Alvarez-Mon M *et al.* Immunomodulatory effect of interferon- α 2b on natural killer cells and T lymphocytes from patients with transitional cell carcinoma of the bladder, 55
 Alvarez-Mon M. *See* Carballido JA, 95
 Amdidouche D. *See* Bonhomme L, 261
 Anai H. *See* Kusumoto H, 33
 Anton R. *See* Dietrich JB, 507
 Antonakis K. *See* Bennani-Baiti MI, 351
 Araya S. *See* Nio Y, 387
 Artioli R. *See* Brambilla C, 3
 Ashino H. *See* Oikawa T, 293
 Astone A *et al.* Salvage chemotherapy with mitoxantrone and mitomycin with or without methotrexate in advanced breast cancer, 471
 Avramoglou T. *See* Morere JF, 629
 Ayele W. *See* Benvenuto JA, 19
- Baba H. *See* Maehara Y, 117
 Banks WA *et al.* Selective uptake of the somatostatin analog RC-160 across the blood-brain tumor barrier of mice with KHT sarcomas, 519
 Barone C. *See* Astone A, 471
 Bastian G. *See* Chevillard S, 133
 Basu S & Sodhi A. Interaction between lymphokine activated cells generated in the presence of cisplatin/FK-565 and tumor cells: transmission electron microscopy analysis, 155
 Batista U. *See* Serša G, 253
 Beck JP. *See* Dietrich JB, 507
 Benassi M. *See* Fanciulli M, 615; *also* Floridi A, 407
 Bennani-Baiti MI *et al.* Potential antineoplastic activity of keto-C-glycosides—a new family of cytostatic agents, 351
 Benvenuti F. *See* Neri B, 87, 696
 Benvenuto JA *et al.* Clinical pharmacokinetics of ifosfamide in combination with N-acetylcysteine, 19
- * S denotes page number in Supplement.
- Berger DP *et al.* Preclinical activity of hepsulfam and busulfan in solid human tumor xenografts and human bone marrow, 531
 Bissery MC. *See* Hanauske A-R, 121
 Bobanović F. *See* Serša G, 253
 Bonfanti M. *See* Taverna P, 401
 Bonhomme L *et al.* Intratumor treatment of C3H mouse mammary carcinoma with 5-fluorouracil adsorbed on activated charcoal particles, 261
 Borg A-L. *See* Stenberg K, 125
 Brambilla C *et al.* Treatment of premenopausal advanced breast cancer with goserelin—a long-acting luteinizing hormone releasing hormone agonist, 3
 Braquet P. *See* Pignol B, 599; *also* Principe P, 577
 Brodar F. *See* Lam KS, 219
 Broquet C. *See* Pignol B, 599; *also* Principe P, 577
 Brown J. *See* Wall JG, 337
 Brown T. *See* Wall JG, 337
 Brown TD. *See* Muggia FM, 211
 Brun A. *See* Salford LG, 267
 Bruno T. *See* Fanciulli M, 615; *also* Floridi A, 407
 Burris III HA. *See* Wall JG, 337
 Burton MA. *See* Napoli S, 47
- Campana F. *See* Chevillard S, 133
 Canti G *et al.* Action spectrum of photoactivated phthalocyanine AlS₂Pc in tumor bearing mice, 139
 Carballido JA *et al.* Analysis of the effect of intravesical treatment with interferon- α 2b on the clinical evolution and on the *in vivo* function of T lymphocytes and natural killer cells in patients with superficial bladder tumors, 95
 Carballido JA. *See* Alvarez-Mon M, 55
 Cassano A. *See* Astone A, 471
 Castagnetti G. *See* Ferrari P, 255
 Catania S. *See* Silvestrini R, 677
 Catapano CV. *See* Taverna P, 401
 Chagnaud JL. *See* Faiderbe S, 541
 Chaitchik S. *See* Inbar M, 375; *also* Merimsky O, 371, 481, 567;
 Chapuis J-C *et al.* Activity of etoposide (VP-16) and teniposide (VM-26) in exponential and plateau phase human tumor cell cultures, 245
- Chaumeron S. *See* Pignol B, 599
 Chen Y. *See* Napoli S, 47
 Chevillard S *et al.* Cytotoxic effects and pharmacokinetic analysis of combined adriamycin and X-ray treatments in human organotypic cell cultures, 133
 Citti L. *See* Taverna P, 401
 Clark GM. *See* Melink TJ, 571; *also* Wall JG, 337
 Codde JP. *See* Napoli S, 47
 Coleman R. *See* Kamthan A, 331
 Colombi L. *See* Neri B, 87, 696
 Conley FK. *See* Banks WA, 519
 Coppey J. *See* Chevillard S, 133
 Corselli G. *See* Serretta V, 195
 Cosolo W. *See* Zhang W, 593
 Coulomb H. *See* Pignol B, 599; *also* Principe P, 577
 Crepin M. *See* Morere JF, 629
 Crougths RJM. Pituitary tumors: diagnosis and treatment, 555
 Cubeddu R. *See* Canti G, 139
 Cunningham KT. *See* Freeman AJ, 79
- Daniels DL. *See* Hall IH, 273
 Daoud SS. Cell membranes as targets for anti-cancer drug action, 443
 De Marco C. *See* Silvestrini R, 677
 De Seze R. *See* Faiderbe S, 541
 Debnath ML. *See* Hall IH, 273
 Degen D. *See* Hanauske A-R, 43, 121, 143
 Delpino A. *See* Floridi A, 407
 Dempke WCM *et al.* Expression of resistance to etoposide and vincristine *in vitro* and *in vivo* after X-irradiation of ovarian tumor cells, 395
 Dengler WA. *See* Berger DP, 531
 Denicoff AM. *See* Pai LH, 463
 Didier AD. *See* Pourtier-Manzanedo A, 419
 Dietrich JB *et al.* Identity of the N-terminal sequences of the three A chains of mistletoe (*Viscum album* L.) lectins—homology with ricin-like plant toxins and single-chain ribosome-inhibiting proteins, 507
 D'Incalci M. *See* Taverna P, 401
 Doré BT & Momparler RL. Effects of 5-aza-2'-deoxycytidine and interferon- α on differentiation and oncogene expression in HL-60 myeloid leukemic cells, 281

- Drzewiecki G. *See* Kandaswami C, 525
Duncan R. Drug-polymer conjugates: potential for improved chemotherapy, 175
- Eich E. *See* Glatt H, 609
Ekman A. *See* Hand AMS, 687
Elis A. *See* Lishner M, 367
Emi Y. *See* Maehara Y, 117
Engelmann U *et al.* Interferon- α 2b instillation prophylaxis in superficial bladder cancer—a prospective, controlled three-armed trial, 335
Eriksson S. *See* Skog S, 379
Escobedo A. *See* Brambilla C, 3
- Faiderbe S *et al.* Curative effects of *all-trans*-retinoic acid on rat sarcomas, 541
Fanciulli M *et al.* Inhibition of membrane redox activity by rhein and adriamycin in human glioma cells, 615
Faure E. *See* Bonhomme L, 261
Ferrari G. *See* Ferrari P, 255
Ferrari P *et al.* Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: interferon- α 2b versus interferon- α 2b with epirubicin, 255
Fiebig HH. *See* Berger DP, 531
Fimiani V & Minniti D. Anti-tumor properties of the organometallic complex *cis*-dimethylbis[sulfinylbis(methane)-S]platinum (II), 9
Fleming TR. *See* Muggia FM, 211
Fletcher WS. *See* Pommier RF, 635
Floridi A *et al.* Survival response of a human glioma cell line to hyperthermia associated with rhein, 407
Floridi A. *See* Fanciulli M, 615
Fontana T. *See* Astone A, 471
Franz H. *See* Dietrich JB, 507
Frayssinet C. *See* Bennani-Baïti MI, 351
Fredj G. *See* Bonhomme L, 261
Freeman AJ *et al.* Selectivity of 5-HT₃ receptor antagonists and anti-emetic mechanisms of action, 79
Friedman C. *See* Wall JG, 337
Fukumoto M. *See* Nio Y, 387
- Gebbia N. *See* Gebbia V, 347
Gebbia V *et al.* Hydroxyurea modulates 5-fluorouracil antineoplastic activity in advanced head and neck carcinoma pretreated with chemotherapy, 347
Geffard M. *See* Faiderbe S, 541
Gemelli MT. *See* Neri B, 87, 696
Gentile FP. *See* Fanciulli M, 615; *also* Floridi A, 407
Gerasimova GK. *See* Mikhaevich IS, 513
Gilmore IT. *See* Owen RR, 101
- Glatt H *et al.* Clavine alkaloids and derivatives as mutagens detected in the Ames test, 609
Glisson BS & Alpeter MD. Multidrug resistance in a small cell lung cancer line: rapid selection with etoposide and differential chemosensitization with cyclosporin A, 359
Godenèche D. *See* Kim-Triana B, 225
Goodman PJ. *See* Muggia FM, 211
Graff J. *See* Engelmann U, 335
Grassi D. *See* Ferrari P, 255
Gray BN. *See* Napoli S, 47
Grindey GB. *See* Hanauske A-R, 143
Guisteau D. *See* Bonhomme L, 261
Gupta-Burt S. *See* Pai LH, 463
- Hagiwara A *et al.* Toxicity of a new dosage format, cisplatin incorporated in lactic acid oligomer microspheres, in mice, 237
Hagiwara A. *See* Sakakura C, 233
Hall ES. *See* Hall IH, 55, 273
Hall IH *et al.* The anti-neoplastic activity of 2,3-dihydrophthalazine-1,4-dione and *N*-butyl-2,3-dihydrophthalazine-1,4-dione in human and murine tumor cells, 55
Hall IH *et al.* The antineoplastic and cytotoxicity of benzohydroxamic acids and related derivatives in murine and human tumor cells, 273
Hamanaka R. *See* Oikawa T, 293
Hanauske A-R *et al.* Preclinical activity of ilmofosine against human tumor colony forming units *in vitro*, 43
Hanauske A-R *et al.* Effects of Taxotere and taxol on *in vitro* colony formation of freshly explanted human tumor cells, 121
Hanauske A-R *et al.* Activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units, 143
Hand AMS *et al.* Interferon- α and - γ in combination with chemotherapeutic drugs: *in vitro* sensitivity studies in four human mesothelioma cell lines, 687
Hasegawa M. *See* Oikawa T, 293
Hasun R. *See* Hoeltl W, 295
Hatty B. *See* Kamthan A, 331
Hayashi H. *See* Nio Y, 387
Heiden T. *See* Skog S, 379
Herscovici J. *See* Bennani-Baïti, 351
Hersh EM. *See* Muggia FM, 211
Hibasami H. *See* Murata T, 683
Hill BT. *See* Dempke WCM, 395
Hilsenbeck SG. *See* Hanauske A-R, 43, 121, 143
Ho BT *et al.* Analgesic activity of anticancer agent suramin, 91
- Hoeltl W *et al.* Prospective, randomized trial to evaluate high-versus low-dose interferon- α 2b versus conventional chemotherapy in prevention of the recurrence of superficial transitional cell carcinoma of the urinary bladder, 295
Hortobagyi GN. *See* Theriault RL, 455
Hoshi A. *See* Nakajima Y, 289
Hosokawa M. *See* Micallef M, 659
Huo YY. *See* Ho BT, 91
Husgafvel-Pursiainen K. *See* Hand AMS, 687
- Iacobini C. *See* Floridi A, 407
Iacopino F. *See* Sica G, 147
Ignatius A & Tempel KH. Influence of suramin on some DNA-directed enzymes and primary cultures of chicken embryo and rat cells, 499
Iigo M. *See* Nakajima Y, 289
Inbar M *et al.* Cisplatin-related Lhermitte's sign, 375
Ingria F. *See* Gebbia V, 347
Ishizuka M. *See* Oikawa T, 293
Israel L. *See* Morere JF, 629
Ito M. *See* Hagiwara A, 237; *also* Sakakura C, 233
Iwaguchi T. *See* Shimizu M, 427
Iwashima A. *See* Nishino H, 493
Izydore R. *See* Hall IH, 273
- Janaky T. *See* Szepeshazi K, 109
Jiwa A. *See* Palma JP, 665
Johnson DL. *See* Banks WA, 519
Johnson R. *See* Wall JG, 337
Jonsson B *et al.* SDZ PSC-838—a novel potent *in vitro* chemosensitizer in multiple myeloma, 641
Jozefonvicz J. *See* Morere JF, 629
Juhasz AV. *See* Szepeshazi K, 109
Jung ML. *See* Dietrich JB, 507
- Kamthan A. *et al.* A phase II study of sulofenur (LY186641) in gastric cancer, 331
Kandaswami C *et al.* Differential inhibition of proliferation of human squamous cell carcinoma, gliosarcoma and embryonic fibroblast-like lung cells in culture by plant flavonoids, 525
Kasper R. *See* Glatt H, 609
Kastin AJ. *See* Banks WA, 519
Katoh A. *See* Lee M, 413
Kawabata K. *See* Nio Y, 387
Kelln RA. *See* Kirkpatrick DL, 651
Keng PC. *See* Chapuis J-C, 245
Khalifa F. *See* Motawy MS, 475
Khokhar AR *et al.* Toxicity and efficacy studies on a series of lipid-soluble dineodecanoato(*trans*-*R,R*- and *trans*-*S,S*-1,2-diaminocyclohexane) platinum (II) complexes entrapped in liposomes, 95

- Kim-Triana B *et al.* Phase I trial of Perri-mustine, a new cysteamine (2-chloro-ethyl) nitrosourea: an inpatient escalation scheme, 225
- Kimura H. *See* Nio Y, 387
- King KM. *See* Kirkpatrick DL, 651
- Kirkpatrick DL *et al.* Effect of hypoxic tumor cell cytotoxic disulfide on the membrane and DNA of tumor cells in culture, 651
- Kiue A. *See* Oikawa T, 293
- Kneuper-Hall R. *See* Wall JG, 337
- Knopf HJ. *See* Engelmann U, 335
- Kobayashi H. *See* Micallef M, 659
- Kohno K. *See* Takano H, 323
- Kohnoe S. *See* Maehara Y, 117
- Kothari L & Subramanian A. A possible modulatory influence of melatonin on representative phase I and II drug metabolizing enzymes in 9,10-dimethyl-1,2-benzanthracene induced rat mammary tumorigenesis, 623
- Krepelka J. *See* Miko M, 63
- Kuhn J. *See* Wall JG, 337
- Kusumoto H *et al.* Relationship between tumor histopathology and *in vitro* sensitivity to antitumor drugs in gastric cancer, 33
- Kusumoto H. *See* Maehara Y, 117
- Kuwano M. *See* Oikawa T, 293; also Takano H, 323
- Lafarge-Frayssinet C. *See* Bennani-Baïti MI, 351
- Lam KS *et al.* Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in cancer patients, 219
- Lamm DL. Guest Editor's introduction (Editorial), 35
- Lamm DL. Diagnosis and treatment of bladder cancer, 395
- Larsson R. *See* Jonsson B, 641
- Lattuada D. *See* Canti G, 139
- Lechuga MJ. *See* Brambilla C, 3
- Lee M *et al.* Interferon modulation of 5-fluorouracil: use in neoadjuvant therapy inhibits experimental liver metastases in nude mice, 413
- Lee M. *See* Hagiwara A, 237
- Legha SS. *See* Benvenuto JA, 19
- Leichman L. *See* Muggia FM, 221
- Leroy E. *See* Canti G, 139
- Letourneur D. *See* Morere JF, 629
- Levin VA. *See* Ho BT, 91
- Linnainmaa K. *See* Hand AMS, 687
- Lishner M *et al.* Late doxorubicin cardiotoxicity, 367
- Loewenstein A. *See* Merimsky O, 371
- Loor F. *See* Pourtier-Manzanedo A, 419
- Lu JG. *See* Ho BT, 91
- Lucas VS. *See* Lam KS, 219
- Ludovici M. *See* Neri B, 87, 696
- Macdonald JS. *See* Muggia FM, 211
- McPhillips JJ. *See* Hanauske A-R, 43
- McVea S. *See* Wall JG, 337
- Madelmont JC. *See* Kim-Triana B, 225
- Maehara Y *et al.* Metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil to 5-fluorouracil in partially hepatectomized rats, 117
- Maehara Y. *See* Kusumoto H, 33
- Maisonnet T. *See* Pignol B, 599
- Mann WS. *See* Wall JG, 337
- Manzano L. *See* Alvarez-Mon M, 55; also Carballido J, 95
- Marchetti P. *See* Sica G, 147
- Marshall MH. *See* Hanauske A-R, 43, 143
- Martins IJ. *See* Napoli S, 47
- Masai Y. *See* Nio Y, 387
- Mathé G. *See* Kim-Triana B, 225
- Mathieu MC. *See* Bonhomme L, 261
- Matias B. *See* Lam KS, 219
- Matsuda T. *See* Takano H, 323
- Matsuno T. *See* Nishino H, 493
- Matsuo K. *See* Takano H, 323
- Mattson K. *See* Hand AMS, 687
- Mattson M. *See* Hand AMS, 687
- Melink TJ *et al.* The impact of phase I clinical trials on the quality of life of patients with cancer, 571
- Mencia-Huerta JM. *See* Pignol B, 599
- Merimsky O & Chaitchik S. Neurotoxicity and interferon- α , 567
- Merimsky O *et al.* Cortical blindness—a catastrophic side effect of vincristine, 371
- Merimsky O *et al.* Salvage cisplatin and adriamycin for advanced or recurrent basal or squamous cell carcinoma of the face, 481
- Merimsky O. *See* Inbar M, 375
- Mestroni G. *See* Sava G, 25
- Meyer C. *See* Nio Y, 387
- Micallef M *et al.* Bleomycin but not its derivatives inhibits the *in vivo* shedding of a rat tumor-associated antigen, 659
- Middleton Jr E. *See* Kandawami C, 525
- Mikhaevich IS *et al.* Antiproliferative effect of complexes of platinum (II) with plasmanyl-(N-acyl)-ethanolamine, an inhibitor of protein kinase C, 513
- Miklavčić D. *See* Serša G, 253
- Miko M *et al.* 9-Hydroxybenfluron: effect on energy-yielding processes in Ehrlich ascites and P388 murine leukemia cells, 63
- Miller III MC. *See* Hall IH, 273
- Milo G. *See* Pommier RF, 635
- Minniti D. *See* Fimiani F, 9
- Misset JL. *See* Kim-Triana B, 225
- Modiano M. *See* Lam KS, 219
- Moltó LM. *See* Alvarez-Mon M, 55; also Carballido J, 95
- Momparler RL. *See* Doré BT, 281
- Monserret R. *See* Bennani-Baïti MI, 351
- Morere JF *et al.* Inhibitory effect of substituted dextrans on MCF7 human breast cancer cell growth *in vitro*, 629
- Morita I. *See* Oikawa T, 293
- Motawy MS *et al.* Mitoxantrone, cytosine-arabinoside and 6-thioguanine (MAT) in the treatment of newly diagnosed acute non-lymphoblastic leukemia in adults, 475
- Motta M. *See* Brambilla C, 3
- Muggia FM *et al.* High incidence of coagulopathy in phase II studies of recombinant tumor necrosis factor in advanced pancreatic and gastric cancers, 211
- Muller CD. *See* Pourtier-Manzanedo A, 419
- Murakoshi M. *See* Nishino H, 493
- Muranishi S. *See* Hagiwara A, 237
- Murata T *et al.* Methylglyoxal bis-(butylamidino)hydrazone exhibits antitumor effect on human malignant melanoma cells but reduces the antitumor action of cisplatin, 683
- Murota S-I. *See* Oikawa T, 293
- Musset M. *See* Kim-Triana B, 225
- Nagy A. *See* Szepeshazi K, 109
- Nakajima Y *et al.* Antitumor effect and tumor level of 5-fluoro-2'-deoxyuridylate following oral administration of tetradecyl 2'-deoxy-5-fluoro-5'-uridylate, 289
- Nakashima K. *See* Murata T, 683
- Napoli S *et al.* Dose response and toxicity of doxorubicin microspheres in a rat tumor model, 47
- Naveau S. *See* Bonhomme L, 261
- Neri B *et al.* Subjective and metabolic effects of clodronate in patients with advanced breast cancer and symptomatic bone metastases, 87; also 696
- Neudorfer M. *See* Merimsky O, 481
- New RRC. *See* Owen RR, 101
- Newman RA. *See* Benvenuto JA, 19; also Ho BT, 91
- Nicaise C. *See* Benvenuto JA, 19
- Nilsson K. *See* Jonsson B, 641
- Nio Y *et al.* A comparative study of the antitumor activities of 5'-deoxy-5-fluorouridine and its prodrug trimethoxy-benzoyl-5'-deoxy-5-fluorocytidine (Ro09-1390) on human digestive organ cancer xenograft lines transplanted in nude mice, 387
- Nishino A. *See* Nishino H, 493
- Nishino H *et al.* Anti-neoplastic effect of halocynthiaxanthin, a metabolite of fucoxanthin, 493
- Nobilis M. *See* Miko M, 63
- Novaković S. *See* Serša G, 253

- Noviello MR. *See* Astone A, 471
 Nygren P. *See* Jonsson B, 641
- O'Rourke T. *See* Wall JG, 337
 Oikawa T *et al.* Effect of 15-deoxy-spergualin, a microbial angiogenesis inhibitor, on the biological activities of bovine vascular endothelial cells, 293
 Okuma M. *See* Takahashi A, 647
 Okuzumi J. *See* Nishino H, 493
 Olivier C. *See* Alvarez-Mon M, 55; *also* Carballido J, 95
 Opri F. *See* Torsten U, 17
 Owen RR *et al.* A phase I clinical evaluation of liposome-entrapped doxorubicin (Lip-Dox) in patients with primary and metastatic hepatic malignancy, 101
 Ozaki K. *See* Sakakura C, 233
 Ozawa H. *See* Shimizu M, 427
- Pacini P. *See* Neri B, 87, 696
 Pacor S. *See* Sava G, 25
 Paggi MG. *See* Fanciulli M, 615
 Pai LH *et al.* Therapy of patients with metastatic breast cancer with 5-fluorouracil, leucovorin and carboplatin, 463
 Palma JP *et al.* Murine macrophage activation after cisplatin or carboplatin treatment, 665
 Patel JP. *See* Motawy MS, 475
 Pavone C. *See* Serretta V, 195
 Pavone-Macaluso M. *See* Serretta V, 195
 Pelin K. *See* Hand AMS, 687
 Peng Y-M. *See* Lam KS, 219
 Perez-Soler R. *See* Khokhar AR, 95
 Perkins E. *See* Kandaswami C, 525
 Pero RW. *See* Salford LG, 267
 Pertz H. *See* Glatt H, 609
 Peters B. *See* Kamthan A, 331
 Pignol B *et al.* Immunomodulatory activity of two new aza alkyl phospholipid antineoplastic drugs, 599
 Planchon P. *See* Morere JF, 629
 Plowman J. *See* Berger DP, 531
 Poirier MC. *See* Pai LH, 463
 Pollastri CA. *See* Ferrari P, 255
 Pommier RF *et al.* Synergistic cytotoxicity of combinations of dimethyl sulfoxide and antineoplastic agents against P388 leukemia in CD-F1 mice, 635
 Pourtier-Manzanedo A *et al.* SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells, 419
 Pozzo C. *See* Astone A, 471
 Price D. *See* Lee M, 413
 Principe P *et al.* Evaluation of combinations of antineoplastic ether phospholipids and chemotherapeutic drugs, 577
- Project Group Bochum-Interferon and Superficial Bladder Cancer. *See* Engelmann U, 335
- Raber MN. *See* Benvenuto JA, 19
 Radulovic S. *See* Banks WA, 519
 Raica M. Effects of intravesical *Corynebacterium parvum* on recurrences of superficial tumors of the urinary bladder, 39
 Rausa L. *See* Gebbia V, 347
 Ravid M. *See* Lishner M, 367
 Reed E. *See* Pai LH, 463
 Ribéreau-Gayon G. *See* Dietrich JB, 507
 Richardson ME. *See* Kirkpatrick DL, 651
 Robustelli della Cuna G. *See* Sica G, 147
 Rodriguez G. *See* Wall JG, 337
 Rose WC. Taxol: a review of its preclinical *in vivo* antitumor activity, 311
 Russo A. *See* Gebbia V, 347
- Sabolovic D. *See* Shimizu M, 427
 Sakakura C *et al.* Enhancement of therapeutic efficacy of aclarubicin against lymph node metastases using a new dosage form: aclarubicin adsorbed on activated carbon particles, 233
 Sakakura C. *See* Hagiwara A, 237
 Salfiti R. *See* Motawy MS, 475
 Salford LG *et al.* Metoclopramide as a sensitizer of 1,3-bis(2-chloroethyl)-1-nitrosourea treatment of brain tumors in the rat, 267
 Sambataro S. *See* Neri B, 87, 696
 Sanfilippo O. *See* Silvestrini R, 677
 Sarosdy M *et al.* High dose versus low-dose intravesical interferon- α 2b in the treatment of carcinoma *in situ*: a randomized, controlled study, 135
 Sasabe T. *See* Hagiwara A, 237
 Sasada M. *See* Takahashi A, 647
 Sasaki S. *See* Sakakura C, 233
 Satomi Y. *See* Nishino H, 493
 Sava G *et al.* Effects of the Ru(III) complexes [mer-RuCl₃(DMSO)₂Im]^o and Na[trans-RuCl₄(DMSO)Im] on solid mouse tumors, 25
 Sawai K. *See* Sakakura C, 233
 Scarffe JH. *See* Kamthan A, 331
 Schally AV. *See* Banks WA, 519; *also* Szepeshazi K, 109
 Sells RA. *See* Owen RR, 101
 Serretta V *et al.* A pilot study comparing different dose levels and administration schedules of interferon- α 2b combined with epirubicin for prevention of recurrence in bladder cancer, 195
 Sersa G *et al.* Anti-tumor effect of electrotherapy alone or in combination with interleukin-2 in mice with sarcoma and melanoma tumors, 253
 Shaffer D. *See* Wall JG, 337
- Shafik A. Intratunical versus parenteral administration of methotrexate, 589
 Shibata T. *See* Micallef M, 659
 Shimamura M. *See* Oikawa T, 293
 Shimizu M *et al.* Cyclophosphamide-induced suppressor cells in nude mice, 427
 Shirasu M. *See* Sakakura C, 233
 Shobayashi S. *See* Hagiwara A, 237; *also* Sakakura C, 233
 Sica G *et al.* Recombinant interferon- α 2b affects proliferation, steroid receptors and sensitivity to tamoxifen of cultured breast cancer cells (CG-5), 147
 Siemann DW. *See* Chapuis J-C, 245; *also* Kirkpatrick DL, 651
 Silvestrini R *et al.* Activity of a chartreusin analog, elsamicin A, on breast cancer cells, 677
 Skog S *et al.* Hydroxyurea-induced cell death in human T lymphoma cells as related to imbalance in DNA/protein cycle and deoxyribonucleotide pools and DNA strand breaks, 379
 Skog S. *See* Stenberg K, 125
 Smith B. *See* Wall JG, 337
 Smyth JF. *See* Kamthan A, 331
 Sodhi A. *See* Basu S, 155
 Soloniuk DS. *See* Kandaswami C, 525
 Spadafora G. *See* Gebbia V, 347
 Spandidos DA. *See* Zoumpourlis V, 163
 Specht S. *See* Lee M, 413
 Spitzer E. *See* Merimsky O, 481
 Stemmler N. *See* Lee M, 413
 Stenberg K *et al.* Comparative studies of galactose-6-mustard and L-phenylalanine mustard on cell growth cycle kinetics *in vitro*, 125
 Stringer RE. *See* Owen RR, 101
 Subramanian A. *See* Kothari L, 623
 Sugimachi K. *See* Kusumoto H, 33; *also* Maehara Y, 117
 Suitiala T. *See* Hand AMS, 687
 Swain SM. *See* Pai LH, 463
 Szepeshazi K *et al.* Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma *in vivo*, 109
- Tagawa T. *See* Murata T, 683
 Takahashi A *et al.* Bone marrow stromal cells attenuate mitoxantrone cytotoxicity against HL-60 leukemic cells, 647
 Takahashi I. *See* Kusumoto H, 33; *also* Maehara Y, 117
 Takahashi T. *See* Hagiwara A, 237; *also* Sakakura C, 233
 Takano H *et al.* DNA topoisomerase-targeting antitumor agents and drug resistance, 323
 Takayasu J. *See* Nishino H, 493
 Takeuchi T. *See* Oikawa T, 293

- Tanaka Y. *See* Nishino H, 493
 Taroni P. *See* Canti G, 139
 Tashima S. *See* Hagiwara A, 237
 Taverna P *et al.* Influence of *O*⁶-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas, 401
 Tavoni F. *See* Ferrari P, 255
 Taylor CW & Yeoman LC. Inhibition of colon tumor cell growth by 8-chloro-cAMP is dependent upon its conversion to 8-chloro-adenosine, 485
 Tempel KH. *See* Ignatius A, 499
 Testa R. *See* Gebbia V, 347
 Theriault RL & Hortobagyi GN. Bone metastasis in breast cancer, 455
 Tokuda H. *See* Nishino H, 493
 Torsten U *et al.* Local therapy of malignant pleural effusion with mitoxantrone, 17
 Tribukait B. *See* Skog S, 379; *also* Stenberg K, 125
 Tseng C-C. *See* Nio Y, 387
 Tsubono M. *See* Nio Y, 387
 Tsushima M. *See* Nishino H, 493
 Tuttle R. *See* Lam KS, 219
 Tyers MB. *See* Freeman AJ, 79
 Uriel J. *See* Bennani-Baïti MI, 351
 Valentini G. *See* Canti G, 139
 Valenza R. *See* Gebbia V, 347
 Vallas M. *See* Hand AMS, 687
 Vandamme B. *See* Pignol B, 599
 Venzon DJ. *See* Pai LH, 463
 Vielh P. *See* Chevillard S, 133
 Vlasenkova NK. *See* Mikhaevich IS, 513
 Vodovnik L. *See* Serša G, 253
 Von Hoff DD. *See* Hanauske A-R, 43, 121, 143; *also* Melink TJ, 571; *also* Wall JG, 337
 Wall JG *et al.* A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days, 337
 Walling J. *See* Kamthan A, 331
 Wallström B. *See* Skog S, 379
 Wargin W. *See* Lam KS, 219
 Weiss G. *See* Wall JG, 337
 Weitzel H. *See* Torsten U, 17
 Whelan RDH. *See* Dempke WCM, 395
 Wigler N. *See* Inbar M, 375
 Winterhalter BR. *See* Berger DP, 531
 Woltering EA. *See* Pommier RF, 635
 Wong OT. *See* Hall IH, 55
 Woodard T. *See* Hall IH, 273
 Yamamoto K. *See* Takahashi A, 647
 Yeoman LC. *See* Taylor CW, 485
 Yoshida M. *See* Kusumoto H, 33; *also* Maehara Y, 117
 Zaffaroni N. *See* Silvestrini R, 677
 Zalcborg JR. *See* Zhang W, 593
 Zerillo G. *See* Gebbia V, 347
 Zhang W *et al.* Interaction of epirubicin with other cytotoxics and anti-emetic drugs, 593
 Zoumpourlis V & Spandidos DA. Hexamethylenebisacetamide stimulates the expression of human immunodeficiency virus long terminal repeat sequence in rat and human fibroblasts, 163